On November 9, 2021 Nektar Therapeutics (NASDAQ:NKTR) reported that it will host a webcast analyst and investor conference call with a cancer specialist and Nektar management on Friday, November 12, 2021, at 12:00 p.m. EST during the 2021 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting (Press release, Nektar Therapeutics, NOV 9, 2021, https://www.prnewswire.com/news-releases/nektar-therapeutics-to-host-webcast-conference-call-for-analysts–investors-with-cancer-specialist-during-2021-society-for-immunotherapy-of-cancer-sitc-36th-annual-meeting-301419303.html [SID1234594922]). The call will be hosted by Nektar management and will include, SITC (Free SITC Whitepaper) author and presenter, Dr. Mehmet Altan, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas Anderson Cancer Center and Dr. Alan Tan, Director of GU Medical Oncology and Assistant Professor in the Division of Hematology, Oncology and Cell Therapy at Rush University Medical Center.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will follow the publication of the NKTR-255 poster (Abstract #957) on Friday morning. SITC (Free SITC Whitepaper) is being held in Washington, D.C. and virtually from November 10 to November 14, 2021.

Analyst Call:

Date and Time: Friday, November 12, 2021, at 12:00 p.m. EST

Dial-in: 877-881-2183 (toll-free) or 970-315-0453 (enter access code 1769208)

Investors and analysts can also view slides and listen to the live audio webcast of the presentation at View Source The event will also be available for replay for two weeks on Nektar’s website: www.nektar.com.

Details of the presentations at SITC (Free SITC Whitepaper) are as follows:

Nektar Poster Presentations at SITC (Free SITC Whitepaper)

Abstract 957: "NKTR-255 Plus Cetuximab in Patients with Solid Tumors: Interim Safety and Efficacy Results from the Phase 1b Dose Escalation Study," Altan, M., et al.

Presenter: Dr. Mehmet Altan, MD Anderson Cancer Center
ePoster and live poster will be available on Friday, November 12th, 2021, at 7:00 a.m. EST
Poster reception: Friday, November 12, 2021, from 7:00 p.m. – 8:30 p.m. EST
Additional Collaborator Presentations at SITC (Free SITC Whitepaper)

Abstract 59: "Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial," Feils, AS., et al.

ePoster will be on display on the SITC (Free SITC Whitepaper) 2021 virtual meeting platform on Friday, November 12, 2021, at 7:00 a.m. EST
Abstract 596: "Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity," Rolig, A., et al.

ePoster will be on display on the SITC (Free SITC Whitepaper) 2021 virtual meeting platform on Friday, November 12, 2021, at 7:00 a.m. EST
Dr. Mehmet Altan

Mehmet Altan, MD, is an Assistant Professor in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas Anderson Cancer Center. Dr. Altan is one of the lead investigators in the phase 1/2, dose-escalation and dose-expansion study of NKTR-255 in combination with cetuximab in patients with refractory 2nd and 3rd line metastatic colorectal cancer or metastatic head and neck cancer. His current research areas include identification of mechanisms for primary and secondary resistance to immunotherapies and predictive markers for immunotherapy toxicities. He also works on translational research projects for identification of spatiotemporal dynamics of the tumor microenvironment in response to immunotherapy to define potential therapeutic targets.

Dr. Alan Tan

Alan Tan, MD, is a Director of GU Medical Oncology and an Assistant Professor in the Division of Hematology, Oncology and Cell Therapy at Rush University Medical Center. He specializes in kidney cancer, urothelial/bladder cancer, prostate cancer and melanoma. Dr. Tan has clinical research interest in designing and implementing clinical trials to test novel immunotherapies and targeted therapies in these cancers. He also leads the Rush University Precision Oncology and Genomics program. He is co-chair for the Hoosier Cancer Research Network (HCRN) Melanoma Working Group.

On November 9, 2021 Bioniz Therapeutics, Inc., a clinical stage biopharmaceutical company developing precision cytokine targeted therapies to treat immuno-inflammatory diseases, reported that management will participate in a fireside chat at the upcoming Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1, 2021, at 1:00pm Eastern Time (Press release, Bioniz Therapeutics, NOV 9, 2021, https://www.prnewswire.com/news-releases/bioniz-therapeutics-to-present-at-evercore-isi-4th-annual-healthconx-conference-301419703.html [SID1234594921]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast of Bioniz’s presentation can be accessed at www.bioniz.com. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.

On November 9, 2021 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that it will take part in a fireside chat at the Stifel Healthcare Conference 2021, which will be webcast on November 16 at 8:20 a.m. P.T. / 11:20 a.m. E.T. David Meek, chief executive officer and Charles Baum, M.D., Ph.D., president, founder and head of research and development, will represent the company (Press release, Mirati, NOV 9, 2021, View Source [SID1234594920]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast will be available through the "Investors and Media" section on Mirati.com and a replay of the webcast will be made available following the event.

On November 9, 2021 Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology reported that it will present two research posters on its HPK1 and STING programs at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting (SITC 2021) taking place on November 10 – 14, 2021, in Washington, DC (Press release, Ryvu Therapeutics, NOV 9, 2021, View Source [SID1234594919]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ryvu will present a poster on novel, orally administered HPK1 inhibitors which exhibit nanomolar activity in an immunosuppressive environment. These small molecules have shown favorable PK profiles allowing for in vivo target engagement after oral administration, and hold promising potential as a treatment in a variety of solid tumor indications.

The second poster will highlight a novel small-molecule STING agonist, RVU-27065. Selective STING pathway activation with RVU-27065 allows for repolarization of immunosuppressive tumor-associated macrophages into a pro-inflammatory phenotype without a negative impact on T-cell function. With favorable drug-like properties and a good safety profile, RVU-27065 is a promising candidate for standalone treatment as well as targeted delivery as a payload for antibodies.

Both posters will be available online as of November 12, at 7 AM ET, and presented during the Poster Session on November 13, at the Walter E. Washington Convention Center in Washington, D.C.

Novel, orally administered HPK1 inhibitors demonstrate anti-tumor efficacy and enhanced immune response (Abstract ID: 752), Maciej Kujawa et al.

On-site presentation session: November 13, 2021, 7:00 AM – 8:30 PM, Poster Hall E

Characterization of RVU-27065 a novel small-molecule STING agonist suitable for systemic administration (Abstract ID: 764), Maciej Rogacki et al.

On-site presentation session: November 13, 2021, 7:00 AM – 8:30 PM, Poster Hall E

To view the abstracts, please visit: View Source

On November 9, 2021 Rarecells, Inc., a healthcare company in the field of liquid biopsy, focused on the development and commercialization of non-invasive tests for early cancer detection, reported that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET -AML test for early detection of acute myeloid leukemia (AML) in patients with myelodysplastic syndrome (MDS) (Press release, RARECELLS, NOV 9, 2021, https://www.prnewswire.com/news-releases/rarecells-inc-to-fund-a-clinical-study-at-columbia-university-of-its-iset–aml-test-for-early-detection-of-acute-myeloid-leukemia-aml-301420287.html [SID1234594918]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study, expected to begin in Q1 2022, will be the first clinical evaluation of the ISET -AML test. Azra Raza, M.D., Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons and Director of the MDS Center at Columbia University’s Herbert Irving Comprehensive Cancer Center, is the study’s principal investigator.

This clinical study aims to assess the clinical performance of the ISET -AML test in the context of early AML detection.

Myelodysplastic syndromes are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells. For roughly 30% of the patients diagnosed with MDS, this type of bone marrow failure syndrome will progress to AML, which is often fatal. Currently, patients with MDS are monitored with blood tests to measure complete blood cell counts and bone marrow analyses to detect the appearance of leukemic blasts heralding the development of AML. However, blood tests have a very low sensitivity to detect rare blasts and bone marrow tests involve an invasive procedure that cannot be repeated frequently. As a result, AML is often diagnosed when it is already well established and may be resistant to available treatment options.

The ISET patented EC-marked platform is able to extract down to one single cancer cell of any type from 10 ml of blood, thus a tumor cell mixed with 100 million leukocytes and 50 billion erythrocytes, according to peer-reviewed published studies. The ISET -AML test uses the ISET platform to extract from blood the rare leukemic blast cells with unsurpassed sensitivity and detect them through suitable markers labelling, image analysis and AI.

Dr. Raza, who wrote the best-selling book "The First Cell and the Human Costs of Pursuing Cancer to the Last," said: "New non-invasive tests are needed to detect the first leukemic cells in the blood of MDS patients so that we can identify and treat patients at risk of developing AML before the disease becomes established."

Patrizia Paterlini, President and Chief Executive Officer of Rarecells, said: "We are pleased to be working with Columbia University’s Herbert Irving Comprehensive Cancer Center to conduct the first clinical evaluation of the ISET -AML test in patients with MDS. The strategic decision to transition the ISET -AML test to an investigator-sponsored study at Columbia will provide access to world-class expertise and has the potential to accelerate patients’ recruitment in order to expedite our clinical study. We look forward to a continued progress across our ISET Early Cancer Detection program, which also includes ongoing studies in patients at risk of Prostate Cancer".